Clinical trials

Current Clinical Trials

Cellcolabs' cells are used in international clinical trials for a number of conditions, including Ageing Frailty, Osteoarthritis (OA), Musculoskeletal Injuries and prevention of various diseases.

As with most other stem cell products, Cellcolabs´ stem cells are classified as an investigational medicinal product (iATMP) and do not yet have market approval. Although research has shown promising clinical outcomes, the underlying mechanism of stem cell treatment has not yet been explicated. As such, clinical trials are necessary to provide more research and data. Cellcolabs supports this work through driving scale in both academic research and our own clinical trials.

If you are interested in joining a clinical trial, visit clinical.cellcolabs.com for more information.

Join a trial with Cellcolabs stem cells

Realizing the potential

Studies have shown that mesenchymal stromal cells (MSCs) reduce inflammation, modulate the immune system, and regenerate damaged or diseased tissues. These properties make MSCs a promising candidate to address a number of chronic diseases whose current treatment methods are insufficient, to accelerate better health and quality of life globally.

Cellcolabs was founded in response to the poor availability and high prices of high-quality stem cells for research and treatments. The high quality of our stem cells is ensured through our production protocol, which is the result of over 20 years of research at the Karolinska Institute in Sweden, including 167 published scientific papers with over 30,000 citations (as of 2021). Furthermore, our MSCs are produced from the bone marrow of rigorously screened, healthy, young donors, to ensure maximal potency.